Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk

Cancer

Volumn 116, Issue 1, 2010, Pages 8-19

  Dupont, William D ^a   Breyer, Joan P ^a   Bradley, Kevin M ^a   Schuyler, Peggy A ^a   Plummer, W Dale ^a   Sanders, Melinda E ^a   Page, David L ^a   Smith, Jeffrey R ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; PP2A; PPP2R1A; Proliferative breast disease; Protein phosphatase 2A

Indexed keywords

HOLOENZYME; PHOSPHOPROTEIN PHOSPHATASE 2A;

ADULT; ALLELE; ARTICLE; BREAST CANCER; BREAST DISEASE; CANCER RISK; CASE CONTROL STUDY; CONTROL GROUP; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; BREAST DISEASES; BREAST NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; HAPLOTYPES; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECANCEROUS CONDITIONS; PROTEIN PHOSPHATASE 2; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 74549141443     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24702     Document Type: Article

References (45)

1. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447:1087-1093.
2. Pant DK, Ghosh A. A systems biology approach for the study of cumulative oncogenes with applications to the MAPK signal transduction pathway. Biophys Chem. 2006;119:49-60.
3. Mumby M. The 3D structure of protein phosphatase 2A: new insights into a ubiquitous regulator of cell signaling. ACS Chem Biol. 2007;2:99-103.
4. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 2001;353(pt 3):417-439.
5. Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science. 1992;257:1261-1264.
6. Gotz J, Probst A, Ehler E, et al. Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit C alpha. Proc Natl Acad Sci U S A. 1998;95:12370-12375.
7. Kao G, Tuck S, Baillie D, et al. C. elegans SUR-6/ PR55 cooperates with LET-92/protein phosphatase 2A and promotes Raf activity independently of inhibitory Akt phosphorylation sites. Development. 2004;131:755-765.
8. Sieburth DS, Sundaram M, Howard RM, et al. A PP2A regulatory subunit positively regulates Ras-mediated signaling during Caenorhabditis elegans vulval induction. Genes Dev. 1999;13:2562-2569.
9. Snaith HA, Armstrong CG, Guo Y, et al. Deficiency of protein phosphatase 2A uncouples the nuclear and centrosome cycles and prevents attachment of microtubules to the kinetochore in Drosophila microtubule star (mts) embryos. J Cell Sci. 1996;109(pt 13):3001-3012.
10. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev. 2005;15:34-41.
11. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell. 2007;130:21-24.
12. Suganuma M, Fujiki H, Suguri H, et al. Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc Natl Acad Sci U S A. 1988;85:1768-1771.
13. Calin GA, di Iasio MG, Caprini E, et al. Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene. 2000;19:1191-1195.
14. Esplin ED, Ramos P, Martinez B, et al. The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function. Genes Chromosomes Cancer. 2006; 45:182-190.
15. Takagi Y, Futamura M, Yamaguchi K, et al. Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut. 2000;47:268-271.
16. Wang SS, Esplin ED, Li JL, et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science. 1998;282:284-287.
17. Chen W, Arroyo JD, Timmons JC, et al. Cancer-associated PP2A A alpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res. 2005;65:8183-8192.
18. Suzuki K, Takahashi K. Induction of E-cadherin endocytosis by loss of protein phosphatase 2A expression in human breast cancers. Biochem Biophys Res Commun. 2006;349:255-260.
19. Hahn WC, Dessain SK, Brooks MW, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol. 2002;22:2111-2123.
20. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449:851-861.
21. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-151.
22. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993;71:1258-1265.
23. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer [see comment]. N Engl J Med. 2005;353:229-237.
24. London SJ, Connolly JL, Schnitt SJ, et al. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992;267:941-944.
25. Page DL, Dupont WD, Rogers LW, et al. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55:2698-2708.
26. Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med. 1998;122:1053-1055.
27. Page DL, Anderson TJ. Diagnostic Histopathology of the Breast. Edinburgh, United Kingdom: Churchill Livingstone; 1987.
28. Page DL, Jensen RA, Simpson JF. Routinely available indicators of prognosis in breast cancer. Breast Cancer Res Treat. 1998;51:195-208.
29. Page DL, Jensen RA, Simpson JF. Premalignant and malignant disease of the breast: the roles of the pathologist. Mod Pathol. 1998;11:120-128.
30. Carlson CS, Eberle MA, Rieder MJ, et al. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet. 2004;74:106-120.
31. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
32. Marchini J, Cutler D, Patterson N, et al. A comparison of phasing algorithms for trios and unrelated individuals. Am J Hum Genet. 2006;78:437-450.
33. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73:1162-1169.
34. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-989.
35. Fallin D, Cohen A, Essioux L, et al. Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer disease. Genome Res. 2001;11:143-151.
36. Mathias RA, Gao P, Goldstein JL, et al. A graphical assessment of p-values from sliding window haplotype tests of association to identify asthma susceptibility loci on chromosome 11q [serial online]. BMC Genet. 2006;7:38.
37. Yaspan BL, Breyer JP, Cai Q, et al. Haplotype analysis of CYP11A1 identifies promoter variants associated with breast cancer risk. Cancer Res. 2007;67:5673-5682.
38. Clark AG. The role of haplotypes in candidate gene studies. Genet Epidemiol. 2004;27:321-333.
39. de Bakker PI, Yelensky R, Pe'er I, et al. Efficiency and power in genetic association studies. Nat Genet. 2005;37:1217-1223.
40. Pe'er I, de Bakker PI, Maller J, et al. Evaluating and improving power in whole-genome association studies using fixed marker sets. Nat Genet. 2006;38:663-667.
41. Schaid DJ. Evaluating associations of haplotypes with traits. Genet Epidemiol. 2004;27:348-364.
42. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39:870-874.
43. Palli D, Rosselli del Turco M, Simoncini R, et al. Benign breast disease and breast cancer: a case-control study in a cohort in Italy. Int J Cancer. 1991;47:703-706.
44. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8:355-368.
45. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007;105:319-326.